MEDICAID AND MORTALITY: NEW EVIDENCE FROM LINKED SURVEY AND ADMINISTRATIVE DATA

Sarah Miller
Norman Johnson
Laura R. Wherry

Working Paper 26081
http://www.nber.org/papers/w26081

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
July 2020, revised August 2020

This paper is released to inform interested parties of research and to encourage discussion. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the U.S. Census Bureau; the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. In addition, any views expressed on statistical, methodological, technical, or operational issues are those of the authors and not necessarily those of the U.S. Census Bureau. These results have been reviewed by the Census Bureau Disclosure Review Board (DRB) to ensure that no confidential information is disclosed. The DRB release numbers are: CBDRB-FY19-310 and CBDRB-FY19-400. The authors gratefully acknowledge the help of J. Clint Carter and John Sullivan in accessing restricted-use Census data. The authors would also like to thank Andrew Goodman-Bacon, Alex Hollingsworth, Jon Gruber, Helen Levy, Kosali Simon, and Ben Sommers for helpful comments and participants at the American Society of Health Economics, Midwest Health Economics Conference, and NBER Summer Institute Health Care meeting. Wherry benefited from facilities and resources provided by the California Center for Population Research at UCLA, which receives core support (R24-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

© 2019 by Sarah Miller, Sean Altekruse, Norman Johnson, and Laura R. Wherry. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source.
ABSTRACT

We use large-scale federal survey data linked to administrative death records to investigate the relationship between Medicaid enrollment and mortality. Our analysis compares changes in mortality for near-elderly adults in states with and without Affordable Care Act Medicaid expansions. We identify adults most likely to benefit using survey information on socioeconomic and citizenship status, and public program participation. We find a 0.132 percentage point decline in annual mortality, a 9.4 percent reduction over the sample mean, associated with Medicaid expansion for this population. The effect is driven by a reduction in disease-related deaths and grows over time. We find no evidence of differential pre-treatment trends in outcomes and no effects among placebo groups.

Sarah Miller
Ross School of Business
University of Michigan
701 Tappan Street
Ann Arbor, MI 48109
and NBER
mille@umich.edu

Laura R. Wherry
University of California at Los Angeles
lwherry@mednet.ucla.edu

Norman Johnson
U.S. Bureau of the Census
norman.j.johnson@census.gov
The Medicaid program is the largest health insurance provider for low income individuals in the United States. Established in 1965, Medicaid currently covers over 72 million enrollees and represents over $500 billion in government spending annually (Centers for Medicare & Medicaid Services, 2019a,b). However, despite the size and scope of this program, we know relatively little about whether Medicaid actually improves the health of its beneficiaries. This is particularly true for low income adults who gained Medicaid eligibility under the Affordable Care Act (ACA), and who are the focus of nearly all of the ongoing policy debate surrounding the program. Studies of the health effects for this group tend to rely on self-reported assessments of health with inconsistent findings across data sources (e.g. Cawley et al., 2018; Courtemanche et al., 2018b; Miller and Wherry, 2017; Sommers et al., 2017). Meanwhile, evidence using objective measures of health, such as mortality, is often inconclusive due to small sample sizes (Baicker et al., 2013; Finkelstein et al., 2012), or the lack of available data linking mortality to individual Medicaid eligibility (Black et al., 2019). The inconclusive nature of these results has led to skepticism among some researchers, policymakers, and members of the media as to whether Medicaid has any positive health impacts for this group.¹

Understanding what types of public programs, if any, are effective at improving the health of low-income individuals is especially important given that they experience dramatically higher mortality rates and worse health outcomes on a number of dimensions than the general population. For example, the annual mortality rate for individuals ages 55 to 64 in households earning less than 138 percent of the Federal Poverty Level (FPL) is 1.7 percent, more than 4 times higher than the 0.4 percent rate experienced by higher-income individuals of the same age.² This low-income group also experiences higher risks of dying from diabetes (by 787%), cardiovascular disease (552%), and respiratory disease (813%) relative to those in higher income households; all of these diseases are at least somewhat amenable to drug therapy. These higher rates of death translate to dramatic differences in life expectancy across income groups. For example, Chetty et al. (2016) find that men at the bottom of the income distribution live on average nearly 15 years less, and women over 10 years less, than those at the top of the income distribution conditional on surviving to age 40. While data from nearly all countries show a positive correlation between income and health, this correlation is stronger in the United States than other high income countries (Semyonov et al., 2013).

Medicaid could play a crucial role in reducing these disparities if it improves access to effective medical care that beneficiaries would not otherwise receive, and recent research suggests this is likely to be the case. For example, Ghosh et al. (2019) find a substantial increase in prescription drug utilization under the ACA Medicaid expansions, including medications for the management of diabetes, treatments for HIV and Hepatitis C, and drug therapies for cardiovascular disease. These particular types of prescription drugs are among those demonstrated to reduce mortality.³ Changes in access to these

¹Flagged as an example of this by Sommers et al. (2017), Congressman Raul Labrador stated that “nobody dies because they don’t have access to health care” during a discussion of Medicaid (Phillips, 2017). Also, Goodman-Bacon et al. (2017) provide a review of media discussion and some academic research suggesting that Medicaid may in fact be harmful to health.

²Authors’ calculations using death rates from 2008 to 2013 derived from the publicly-available National Health Interview Survey Linked Mortality File (National Center for Health Statistics, 2019) for adults with incomes below 138% FPL and those with incomes 400% FPL or greater. We chose these two income cutoffs since adults with incomes below 138% FPL qualify for Medicaid in states that expanded their programs to include low-income adults under the ACA; also, adults with incomes below 400% FPL qualify for subsidies for private insurance coverage.

³Systematic reviews and meta-analyses of randomized, controlled trials find significant decreases in all-cause and
medications are likely to be particularly important for this population given their higher prevalence of chronic disease (Karaca-Mandic et al., 2017). Medicaid coverage may also affect health if it leads to earlier detection and treatment of life-threatening health conditions. Existing research has documented increased screening of treatable cancers such as breast and cervical cancer with expanded Medicaid coverage (Finkelstein et al., 2012; Sabik et al., 2018), as well as the detection of cancer both overall and at an early stage (Soni et al., 2018) and improved access to cancer surgery (Éguia et al., 2018). Furthermore, Medicaid coverage increases the number of hospitalizations, procedures performed in the hospital, and the number of emergency department visits for conditions that require immediate care (Duggan et al., 2019; Finkelstein et al., 2012; Taubman et al., 2014), all of which are likely to be associated with serious medical issues that require treatment. In addition to increasing the provision of these types of ostensibly high value services, Medicaid also increases the use of a variety of other types of medical care such as routine screening for chronic illnesses, outpatient physician visits, use of prescription drugs that aid in smoking cessation, and dental care which also have the potential to improve health over the longer term.4

In this paper, we provide new evidence of the impact of Medicaid on health by using administrative mortality data linked to large-scale, individual survey records. We use this novel dataset to examine the impact of a sizeable Medicaid eligibility expansion that occurred in some states as the result of the ACA. In 2014, the ACA expanded eligibility for the Medicaid program to include all adults in families with incomes under 138 percent of the Federal Poverty Level (FPL). Previously only pregnant women, adults with disabilities, and very low income parents tended to qualify for Medicaid coverage. Although intended to apply to all states, a 2012 Supreme Court decision made the Medicaid eligibility expansion optional. As a result, only 29 states and the District of Columbia expanded coverage in 2014, with 7 additional states electing to expand over the next several years. Despite non-universal adoption, the ACA Medicaid expansions still represent a historic expansion in insurance coverage. Approximately 13.6 million adults gained Medicaid coverage under the ACA (Medicaid and CHIP Payment and Access Commission, 2018); for comparison, Medicare enrolled about 19 million elderly beneficiaries after its creation in 1965 (Bureau of the Census, 1969). We take advantage of variation in state adoption of this large expansion in coverage to compare changes in mortality among individuals in expansion states and non-expansion states.

In contrast to prior research that relies on death certificate data with limited information on individual characteristics, our data include detailed survey measures collected from the 2008 to 2013 years of the American Community Survey (ACS). This large-scale national survey contains approximately 4 million respondents in each year and allows us to observe information on specific characteristics that determine Medicaid eligibility including income, citizenship status, and the receipt of other social assistance. With this information, we are able to identify individuals who were most likely to benefit from the ACA Medicaid eligibility expansions and, in this way, overcome the inherent limitations present in existing studies that rely only on aggregate death records. We focus on those in this group who were cardiovascular mortality for adults who receive statins (Chou et al., 2016) and decreased all-cause mortality for Type 2 diabetics receiving glucose-lowering drugs (Zheng et al., 2018). In addition, systematic reviews of observational studies indicate decreased mortality among HIV-infected adults initiating anti-retroviral therapy (Chou et al., 2005), as well as indirect evidence of decreased mortality linked to cured infection under antiviral treatment for Hepatitis C (Moyer, 2013).

4See, for example, Finkelstein et al. (2012); Nasseh and Vujicic (2017); Semyonov et al. (2013). Gruber and Sommers (2019) provide a summary of the evidence to date on the impact of the ACA expansions on health care utilization.
between the ages of 55 and 64 in 2014, who are at greater risk of mortality, although we also present results for all non-elderly adults. We follow individuals in our sample over time to examine changes in mortality associated with Medicaid expansion by linking them to the Census Numident file, which contains administrative records on the date of death for all individuals with Social Security Numbers (SSNs) who die in the United States. This file allows us to observe mortality rates for our sample through 2017, four years after the initial ACA Medicaid eligibility expansions. Despite the high-quality of the death information in the Census Numident file, it does not include cause of death information. In supplemental analyses, we further examine changes in mortality by the underlying cause of death using data from the Mortality Disparities in American Communities (MDAC) project, which links the 2008 year of the ACS to death certificate records using the National Death Index.

Our analysis shows that the ACA Medicaid expansions reduced mortality among this targeted group. Prior to the expansions, individuals in our sample residing in expansion and non-expansion states had very similar trends in both Medicaid coverage and mortality. At the time of the expansion, the trajectories of these two groups diverged significantly, with expansion state residents seeing increases in Medicaid coverage and overall insurance coverage, and decreases in annual mortality rates. In the first year following the coverage expansion, the probability of mortality declined by about 0.089 percentage points, or 6.4 percent relative to the sample mean. The estimated impact of the expansions increases over time, suggesting that prolonged exposure to Medicaid results in increasing health improvements. By year 4, residents of expansion states have an annual mortality rate that is 0.208 percentage points lower than their non-expansion state counterparts. In our supplemental analysis using the MDAC data, we find evidence that healthcare amenable and internal (disease-related) causes of death were reduced by the expansions, but no evidence that deaths due to external causes, such as car accidents, fell. We also conduct several placebo tests to assess the validity of our analysis including examining the impact of the expansions on those age 65 or older in 2014 who did not gain Medicaid eligibility; examining the effect on individuals in higher income households who were less likely to be affected; and, restricting the analysis sample to the pre-ACA period. We find no relative change in coverage or mortality across expansion and non-expansion states among the elderly or in the pre-ACA period, settings in which no Medicaid expansion occurred. Among those in higher income households, we find small but statistically significant increases in Medicaid coverage and similarly small decreases in mortality, consistent with a causal impact of Medicaid on mortality.

Our analysis provides new evidence that Medicaid coverage reduces mortality rates among low-income adults. Our estimates suggest that approximately 15,600 deaths would have been averted had the ACA expansions been adopted nationwide as originally intended by the ACA. This highlights an ongoing cost to non-adoption that should be relevant to both state policymakers and their constituents.

1 Background

Many studies have shown that Medicaid coverage increases access to and use of health care and reduces financial burden for low-income adults, but evidence as to whether it improves their health remains limited. Studies that do examine health tend to rely on self-reported health measures from survey

5See, e.g., Abramowitz, 2018; Allen et al., 2017; Baicker et al., 2013; Brevoort et al., 2019; Buchmueller et al., 2016; Caswell and Waidmann, 2017; Courtemanche et al., 2017; Finkelstein et al., 2012; Gallagher et al., 2019; Ghosh et al., 2019; Hu et al., 2018; Miller and Wherry, 2017, 2019; Simon et al., 2017; Sommers et al., 2015, 2017.
The evidence from these studies spans from estimated large or modest improvements in reported health associated with Medicaid expansion (Cawley et al., 2018; Simon et al., 2017; Sommers et al., 2016, 2017), to no effects (Courtemanche et al., 2018a,b; Wherry and Miller, 2016) or even small but marginally significant negative effects (Miller and Wherry, 2017).\(^6\)

One concern with self-reported health data is that it may not accurately measure changes in physical health. In the Oregon Health Insurance Experiment (OHIE), low-income adults selected by a lottery to apply for Medicaid coverage reported near immediate improvements in their health compared to the controls, despite experiencing no significant differences yet in their health care utilization (Finkelstein et al., 2012).\(^7\) The researchers concluded that the change in reported health may at least partly capture a general sense of improved well-being, or “winning” effects resulting from individuals’ lottery selection. There is also the risk that changes in self-reported health may reflect increasing awareness of health problems or interactions with the health care system, rather than actual changes in physical health. One example would be increased contact with health providers leading to new information about a previously undiagnosed illness and, as a consequence, a worsened self-perception of health. This could bias downwards estimates of the effect of public health insurance on health.\(^8\) Finally, in general, the reliability of self-reported health measures for U.S. adults and their association with objective health measures are documented to be worse among lower socioeconomic status groups (Dowd and Zajacova, 2007, 2010; Zajacova and Dowd, 2011).

In addition to offering the first experimental evidence on the effects of expanded Medicaid, the Oregon Health Insurance Experiment (OHIE) covered new ground by collecting data on clinical health measures among its participants. The researchers did not observe significant effects on any of the collected measures (blood pressure, cholesterol, and blood sugar levels). Using administrative data, they also found no evidence that Medicaid coverage led to a reduction in mortality during the 16 months following coverage gain. Their estimate suggested a 16 percent reduction in mortality associated with acquiring Medicaid, but with a large confidence interval that could not rule out sizeable changes in either direction.\(^9\)

As the data become available, researchers are beginning to evaluate the mortality effects of the ACA Medicaid expansions.\(^10\) Two current studies use population-level mortality data to estimate changes

\(^6\)Note that neither the time period of study nor the data sources used seem to explain these inconsistencies. In a series of papers studying expansions in two states (AR and KY), Sommers et al. (2015, 2016, 2017) find evidence of significant health improvements emerging only in the second year of expansion. However, in a national study, Courtemanche et al. (2018a,b) find no evidence of improvements in self-reported health due to expansion during any of the first three years of implementation. Using the same data source as these authors, Simon et al. (2017) and Cawley et al. (2018) find evidence of sizable health improvements over the same period. Finally, Miller and Wherry (2019) trace out the effects of Medicaid expansion during each of the first four years of implementation, using a different data source, and find no evidence of improvements in self-reported health.

\(^7\)The researchers found an improvement in self-reported health for the treatment group during their initial survey, which was conducted, on average, about one month after gaining coverage, that was about two-thirds of the size of their main effect estimated using survey data collected more than a year later.

\(^8\)This bias could also operate in the opposite direction if increased interaction with providers improves one’s perception of health. See Currie and Gruber (1995) for more discussion.

\(^9\)Another relevant randomized social experiment provided Medicare to newly entitled Social Security Disability Insurance (SSDI) beneficiaries (as opposed to them being subject to a 2-year waiting period for coverage). The evaluation of this experiment found no reductions in mortality up to 3 years later but the sample sizes were too small to be able to detect effects (Weathers and Stegman, 2012).

\(^10\)A separate but related literature has examined the relationship between public health insurance and child mortality using variation in exposure tied to the introduction of Medicaid and later expansions in public coverage under Medicaid and
in adult mortality in expansion states compared to non-expansion states. In contrast to Oregon, the ACA Medicaid expansions affected a much larger number of people (13.6 million vs. under 11,000) (Finkelstein et al., 2012; Medicaid and CHIP Payment and Access Commission, 2018). However, the authors rely on death certificate data without the information on individual income needed to identify the policy’s target population. As a consequence, it can be difficult to detect effects at the population-level, particularly when Medicaid coverage is estimated to have increased by as little as 1 percentage point among all nonelderly adults (Black et al., 2019). The two studies examining the effects of the ACA Medicaid expansions in this manner reach different conclusions, detecting no (Black et al., 2019) and sizeable effects on adult mortality (a 3.6% reduction) (Borgschulte and Vogler, 2019). In addition, research on pre-ACA expansions in Medicaid that also relies on aggregated data finds larger effects on adult mortality. Sommers et al. (2012) and Sommers (2017) find a 6 percent reduction in nonelderly adult mortality in pre-ACA Medicaid expansions in New York, Maine, and Arizona measured over a five-year period.11 The absence of conclusive evidence on whether Medicaid improves the objective health of adult beneficiaries is a major omission given that Medicaid is a public health program that aims to improve access to and use of efficacious health care.

All of these studies rely on changes in survival for the Medicaid eligible to translate into overall mortality effects observable at the population (or state) level. However, at least two studies suggest that a focus on subgroups most at risk for mortality may increase the likelihood of detecting effects. Swaminathan et al. (2018) examine the impact of the ACA Medicaid expansions on the one-year survival rate of patients with end stage renal disease initiating dialysis. The authors find a significant 8.5 percent reduction in mortality for individuals with this chronic condition, driven primarily by a decrease in deaths due to causes considered health care amenable. More recently, Khatana et al. (2019) find evidence of a decrease in rates of cardiovascular disease among adults ages 45-64 associated with state adoption of the ACA Medicaid expansions.

For this reason, it is likely that the primary impediment to analyzing the impact of Medicaid on mortality has been data availability. Data from death certificate records contain very little socioeconomic information on the decedent; in particular, they contain no information on the decedent’s income, whether he or she previously had health insurance coverage, or other characteristics that might affect Medicaid eligibility. Without data that links information on individual Medicaid eligibility and mortality, researchers must rely on eligibility changes over larger population groups – for example, residents of certain states or counties – which contain many individuals who are not directly affected by Medicaid policy. This decreases the power to detect changes in mortality of a plausible magnitude, leading some researchers to conclude that “it will be extremely challenging for a study [on the ACA Medicaid expansions] to reliably detect effects of insurance coverage on mortality unless these data can be linked at the individual level to large-sample panel data” (Black et al., 2019).

This finding of mortality effects for certain subgroups that may not be detectable in larger aggregations of data is consistent with existing work on the effects of Medicare on health. Card et al. the Children’s Health Insurance Program. For the most part, these studies have found significant declines in mortality associated with expanded coverage for infants and children both in the short-term (e.g. Currie and Gruber, 1996a,b; Goodman-Bacon, 2018b; Howell et al., 2010) and long-term (Brown et al., 2018; Goodman-Bacon, 2016; Wherry and Meyer, 2016).

11In addition, an analysis of the mortality effects of insurance expansion under Massachusetts’s 2006 health reform by Sommers et al. (2014) finds a significant 2.9 percent reduction in all-cause mortality over four years of follow-up.
(2004) and Finkelstein and McKnight (2008) find little evidence of an effect of Medicare on mortality using death certificate records. However, among those who are hospitalized and severely ill, Card et al. (2009) find a significant 1 percentage point (or 20 percent) reduction in mortality following admission that persists for at least 9 months following discharge. This analysis notably identifies these effects by comparing patients just below and above the Medicare-eligible age of 65 when admitted, which is just above the age range considered in our analyses.

It is also worth noting that, at the time of these studies, Medicare did not provide coverage for prescription drugs. Recent papers studying the introduction of prescription drug coverage under the Medicare Part D program find evidence of mortality declines. Huh and Reif (2017) focus on those age 66 and find that insurance coverage for prescription drugs reduces mortality in this group by about 0.16 percentage points annually (about 9.6 percent). Dunn and Shapiro (2019) find slightly larger effects in an analysis that incorporates individuals with older ages. For both papers, reductions in mortality are driven by a decline in deaths due to cardiovascular disease. Using data for a subset of Medicare beneficiaries, Kaestner et al. (2017) find no significant effect on mortality but do document reductions in hospitalization admissions for heart disease, respiratory disease, and diabetes under the program. Importantly, sizeable increases in the use of prescription drugs that treat these particular diseases have been documented under the ACA Medicaid expansions (see Ghosh et al., 2019).

2 Data and Outcomes
To conduct our analysis, we use data from two sources. First, we select respondents from the 2008 to 2013 waves of the American Community Survey who, based on their pre-ACA characteristics, were likely to benefit from the ACA Medicaid expansions. We include only individuals who either are in households with income at or under 138 percent of the FPL or who have less than a high school degree. Since we only have information on income captured at one point in time, the latter criterion is used to identify individuals who are of low socioeconomic status but might not meet the income cutoff at the time of the ACS interview. We exclude non-citizens, many of whom are not eligible for Medicaid, and those receiving Supplemental Security Income (SSI), who are likely to be Medicaid eligible in the absence of the expansions. We restrict our primary analysis to individuals who were ages 55 to 64 in 2014. This higher age group has relatively high mortality rates, and is also consistent with the sample criteria used in Black et al. (2019). We present results for all non-elderly adults in a supplementary analysis. Finally, we exclude residents of 4 states and DC that expanded Medicaid to low-income adults prior to 2014. There are approximately 566,000 respondents who meet our sample criteria.

Descriptive statistics for the sample by state Medicaid expansion status are reported in Table A1. The average age of the respondents in the two groups is similar. However, individuals in expansion states are slightly better off with higher average income (147% of the FPL vs. 140%) and educational attainment (45.3% with less than high school education vs. 46.8%), as well as lower baseline rates of

---

12 Results are similar if we include only those with less than a high school degree, or only those with incomes under 138 percent of the FPL, rather than defining the sample using the union of these two criteria.
13 SSI recipients are automatically eligible for Medicaid coverage in most states.
14 DE, MA, NY, and VT all expanded coverage to individuals with incomes reaching the poverty line or greater prior to the ACA; DC received approval to implement its ACA Medicaid expansion early with enrollment starting in 2011.
15 Note that Census disclosure rules prohibit the disclosure of exact sample sizes and require rounding. All sample sizes reported in this paper are therefore rounded according to these rules.
uninsurance (32.6% vs. 37.3%), than individuals in non-expansion states. In addition, individuals in expansion states are more likely to be white or Hispanic, while a higher share of those in non-expansion states are black.

These data are linked to the Census Numident file. The Census Numident file is derived from the Social Security Administration (SSA) Numerical Identification file, which includes information on date and county of birth and date of death (if it has occurred) for individuals with a Social Security Number (SSN). These data have been used in, e.g., Brown et al. (2018); Chetty et al. (2011, 2016); Dobbie and Song (2015); Sullivan and von Wachter (2009), and other research relying on death information from tax records. Total deaths reported in the SSA file by age and year closely track the numbers reported by the National Center for Health Statistics (Chetty et al., 2016). In addition to this death information from the SSA, the Census Bureau also has information on date of death from the National Death Index (NDI) for some individuals and years, which it incorporates into its date of death measure when available. The Census Bureau updates its Numident file each year with new information from the SSA Numerical Identification file. It formats the data so that there is a single record per individual, reflecting the most accurate and up-to-date information at that point in time. We use the most recently available version of the Census Numident, which captures date of death through the second quarter of 2018. Because we observe only a partial year in 2018, we limit our analyses to deaths occurring in 2017 and earlier.

The Census Numident and ACS data are linked via the Census Bureau’s Personal Identification Validation System (PVS). This system assigns individuals in each dataset a protected identification key (PIK), an anonymized identifier that allows Census to track individuals across datasets. Approximately 94 percent of all ACS respondents are successfully assigned a PIK using available information on name, address, and date of birth, with a slightly higher match rates for citizens (95 percent) (Wagner and Layne, 2014). The assignment of a PIK allows respondents in the ACS to be matched to the Census Numident file. PIKS for the Census Numident file are assigned using social security numbers (SSNs). Since our analysis is restricted to older citizens, and since nearly all American citizens have SSNs assigned by the time they reach adulthood (see Bernstein et al., 2018), we expect to have nearly full coverage of deaths in the Numident file.

Once these data are linked, we observe the vital status of each individual during the year they respond to the ACS and each subsequent year. For example, we observe the vital status of an individual who responds to the 2008 ACS during each year from 2008 through 2017; for an individual who responds to the 2013 ACS, we observe his or her vital status from 2013 through 2017. We construct our outcome measure to represent mortality during each calendar year. If the individual is alive in a given year, the outcome variable takes a value of 0; if that individual died in that year it takes a value of 1. Once an individual has died, he or she is removed from the sample for subsequent years. In this way, we will be able to measure changes in the annual probability of death during a given year among individuals who were alive at the beginning of that year.

The annual mortality rate is about 1.4 percent for our sample on average across all years, and approximately 1.3 percent among respondents in expansion states during the year just prior to expan-

---

16 The NDI collects detailed information on deaths from state vital statistics offices. Respondents to the 2008 ACS were linked to the NDI for the years 2008-2015, as part of the Mortality Disparities in American Communities project.
Note that because we have a fixed sample that ages in each period, mortality rates increase over time (i.e., our sample is oldest in the last year, 2017). In this way, our analysis tracks the mortality trajectory for a fixed cohort defined as adults ages 55 to 64 in 2014 and is representative of the outcomes over time for this group.

While our data uniquely offer the opportunity to link mortality and economic variables at the individual level, there are also several important limitations. First, we observe the economic characteristics of individuals (income and educational attainment, receipt of social services, and citizenship status) at the time they respond to the ACS in the pre-period, between 2008 and 2013. These are time-varying characteristics, however, and may not accurately reflect economic characteristics at the time of the Medicaid expansions for some members of our sample. For example, an individual in a low-income household in 2008 may be in a higher-income household by 2014, at the time the expansions occurred. Similarly, individuals may migrate to different states between the time they responded to the ACS and the time the expansions occurred, resulting in our misclassification of whether that individual was exposed to the eligibility expansion. Note, however, that individual migration decisions do not appear to be correlated with state Medicaid expansion (Goodman, 2017). In general, we expect that this type of misclassification will bias our estimates towards zero.

A second limitation is that our data do not include information on the cause of death. The death information in the Census Numident is derived primarily from the Social Security Administration death records, which contain only date of death. We therefore supplement our main analysis with data from the 2008 year of the ACS, which was linked to death certificate records from 2008 to 2015 as part of the Mortality Disparities in American Communities (MDAC) project. While this drastically reduces both the sample size and follow-up period, it does allow us to conduct exploratory analyses of changes in mortality based on the underlying cause of death as reported on the death certificate.

## 3 Empirical Strategy

Our empirical strategy looks at changes in annual mortality in the expansion states relative to the non-expansion states before and after the implementation of the ACA Medicaid expansions. We estimate this using an event-study model that allows us to assess the evolution of relative outcomes while controlling for fixed differences across states and national trends over time. We estimate:

\[
\text{Died}_{isjt} = \text{Expansion}_s \times \sum_{y=-6}^{3} \beta_y I(t - t_s^* = y) + \beta_t + \beta_s + \beta_j + \gamma I(j = t) + \epsilon_{isjt}. \tag{1}
\]

As described earlier, our data is constructed at the individual \(i\) by year \(t\) level. Each individual responds to the ACS during a survey wave \(j\) and reports their state of residence \(s\). The dependent variable \(\text{Died}_{isjt}\) denotes death during each year \(t\) among individuals who were alive at the beginning of year \(t\). We only observe mortality over a partial year during the year of the individual’s ACS interview \(j\), since that individual had to be alive in order to respond to the survey. To account for this, we include an indicator variable that year \(t\) is the year that the individual responded to the ACS (i.e.,

\[^{17}\text{These annual averages are calculated excluding mortality rates for individuals during their year of ACS interview.}\]
that \( j = t \)). In this equation, \( \beta_s \) denotes state fixed effects and \( \beta_j \) denotes fixed effects associated with each survey wave. \( \beta_t \) denotes calendar year fixed effects, which will account for general trends in mortality for all individuals in our sample, including their gradual aging over time.

The variable \( \text{Expansion}_s \) equals 1 if individual \( i \) was living in a state that opted to expand Medicaid eligibility between 2014 and 2017, and zero otherwise. Indicator variables \( I(t - t^*_s = y) \) measure the time relative to the implementation year, \( t^*_s \), of the expansion in each state, and are zero in all periods for non-expansion states. While most states expanded in the beginning of 2014, some states expanded later in the year or in subsequent years. If a state expanded on or after July 1 of a given year, we code it as having expanded in the subsequent year. The omitted category is \( y = -1 \), the year prior to the expansion. Therefore, each estimate of \( \beta_y \) provides the change in outcomes in expansion states relative to non-expansion states during year \( y \), as measured from the year immediately prior to expansion.

If mortality rates for expansion and non-expansion states were trending similarly prior to the ACA, we expect that estimated coefficients associated with event times \( y = -6 \) to \( y = -2 \) will be small and not statistically significant. We estimate equation (1) with a linear probability model and report heteroskedasticity-robust standard errors that are clustered at the state level. All analyses use ACS survey weights.

In addition to the event study analyses, we also present difference-in-differences (DD) estimates as a summary of the effect across all post-expansion years. These are estimated using the same equation except that the event study indicators are replaced with a single variable denoting an expansion state during the post period (\( \text{Expansion}_s \times \text{Post}_t \)). Recent work by Goodman-Bacon (2018a) shows that the estimates from a two-way fixed effects DD estimator that uses variation in treatment timing, such as this one, can be biased in the presence of time-varying treatment effects. However, we expect that this is unlikely to be a major concern in our context given that we have so few late adopter states and a relatively short post period.

4 Results

4.1 Impact of ACA Expansions on Medicaid Eligibility and Enrollment

We first estimate the impact of the ACA Medicaid expansions on Medicaid eligibility and coverage for individuals similar to those in our sample. We consider changes in eligibility for Medicaid in addition to enrollment changes since eligible individuals are “conditionally covered” by the program, in the sense that they may choose to remain uninsured and enroll only when they become ill. This concept

---

18 Note that we do not have information on the date of the ACS interview. If we drop the observations for which we observe less than a full year of mortality our results are unchanged.

19 Results are also virtually identical in a model that includes controls for gender, race, and single year of age.

20 We group together \( y \leq -6 \) into a single indicator variable interacted with expansion status since we only observe \( y < -6 \) for late expander states.

21 In our analyses, states that expanded Medicaid in 2014 are AR, AZ, CA, CO, CT, HI, IL, IA, KY, MD, MI, MN, NJ, NM, NV, ND, OH, OR, RI, WA, and WV. Michigan implemented their expansion in April 2014 with the remainder of states expanding in January 2014. States that we considered to have 2015 expansions are NH (implemented August 15, 2014), PA (January 1, 2015), and IN (February 1, 2015). We consider AK (September 1, 2015) and MT (January 1, 2016) to be 2016 expansion states and LA (July 1, 2016) to be a 2017 expansion state.

22 In his paper, Goodman-Bacon (2018a) compares the DD estimate to the average of the event study coefficients in the post period to assess whether there this type of bias may be present. When we undertake a similar exercise for our main specification, we arrive at a similarly sized estimate (~0.001320 DD estimate vs. ~0.001367 average of ES coefficients), providing some reassurance that this is likely not a concern for our analyses.
of conditional coverage was first discussed by Cutler and Gruber (1996) in their study of historic Medicaid expansions for pregnant women and children; it may be even more relevant in our context, however, given another change under the ACA designed to make it easier for the uninsured to gain immediate access to Medicaid-funded services. For the first time, the federal government required states to implement presumptive eligibility programs under their Medicaid programs. Specifically, the ACA granted hospitals the ability to make presumptive eligibility determinations for Medicaid for certain groups covered in their state, including the non-elderly ACA expansion population (Caucci, 2014). This means that if patients appear to have incomes low enough to qualify for Medicaid, hospitals may grant temporary Medicaid enrollment. Recipients of this temporary enrollment status may immediately receive health services and providers are guaranteed reimbursement for those services. In addition to presumptive eligibility programs, federal law directs states to provide retroactive coverage for new enrollees by covering medical bills incurred up to 3 months prior to their application date if they met the eligibility criteria during that time. By not requiring an individual to first enroll in Medicaid prior to receiving Medicaid-funded care, these policies reinforce the notion that all eligible individuals are effectively covered by the program even if not actually enrolled.

Since we only observe our sample in the ACS during the pre-expansion years, we do not have information on their economic characteristics or coverage decisions during the post-expansion period. However, we are able to estimate model (1) using respondents in the 2008 to 2017 waves of the ACS who were ages 55 to 64 in 2014, and otherwise meet the same sample definition as used in our main analyses. While repeated cross-sectional data for this cohort does not exactly mirror the individual panel data used to study mortality, it allows us to provide an estimate of the changes in eligibility and insurance coverage likely similar to those experienced by our mortality sample. We impute income eligibility for Medicaid using information on family structure and income and state-specific eligibility criteria over this time period. In addition to changes in Medicaid eligibility, we also examine changes in Medicaid coverage and overall insurance status using respondent reports about current health insurance coverage at the time of the ACS survey.

The results are presented in Figure 1 and in the first three columns of Table 1. We find a large increase in Medicaid eligibility associated with the ACA Medicaid expansions with gains of between 41 and 46 percentage points during each post-expansion year, as compared to the year just prior to expansion. Consistent with many other studies of this policy, we also find significant increases in Medicaid coverage and decreases in uninsurance associated with the decision to expand Medicaid eligibility. Reported Medicaid coverage increases by 7.3 percentage points in the first year and by

---

23 Previously presumptive eligibility programs were optional for states and limited to pregnant women and children. States also had discretion over what types of providers could grant presumptive eligibility for these groups.

24 A handful of states (AR, IA, IN, NH) had federal waivers to waive retroactive coverage for the expansion population, or other existing Medicaid eligibility groups, during our study period (Musumeci and Rudowitz, 2017).

25 There is one additional difference in the setup of this analysis. To avoid having multiple samples disclosed from the restricted-use data, we use the public-use ACS files for this “first-stage” analysis. The public-use file is a two-thirds random sample of the restricted-use file and will therefore result in nearly identical results, but with slightly larger confidence intervals.

26 We consider eligibility for low-income parents under Medicaid Section 1931 criteria in each state, as well as expanded eligibility for parents and childless adults under waiver programs that offered comparable coverage to the ACA Medicaid expansions. Please see Appendix Section B for additional details about the eligibility imputation.

27 E.g., Buchmueller et al. (2016); Cawley et al. (2018); Courtemanche et al. (2017); Miller and Wherry (2017, 2019); Sommers et al. (2015)
9.9 percentage points four years after the expansion relative to the year prior to expansion, while
uninsurance decreases by 3.8 percentage points in the first year and 3.9 percentage points four
years after the expansion. The estimates for years 2 and 3 are larger than those for year 4, which likely
reflects the increasing share of the sample that is aging into Medicare over the study period.

It is important to note that the increases in Medicaid coverage observed in the survey data are
most likely smaller than actual enrollment changes for two reasons. First, Medicaid coverage is notori-
ously underreported in survey data. Boudreaux et al. (2015) link the 2009 ACS to administrative data
on Medicaid and Children Health Insurance Program (CHIP) enrollment and find that 23 percent of
Medicaid/CHIP enrollees do not report this source of coverage. Rates of underreporting are higher for
adults and minority groups; in addition, these groups are more likely to report no insurance coverage
than other sources of coverage. This misreporting results in a large downward bias in estimates of
the coverage effects of the ACA; Boudreaux et al. (2019) find that the impact of the ACA Medicaid
expansions on Medicaid enrollment is 40% smaller when estimated using the ACS rather than admin-
istrative records. Second, by asking about coverage only at the time of the survey, the ACS does not
capture information on Medicaid coverage for individuals enrolled in Medicaid at other times during the
year. Given that there is tremendous churn among adults in the Medicaid program, these estimates,
therefore, likely underrepresent the total share of adults gaining any Medicaid coverage during each
year, which is the relevant exposure measure.

We conduct our own analysis of underreporting for individuals meeting our sample criteria using
data available from the 2008 to 2012 National Health Interview Survey (NHIS) for respondents linked to
administrative data on Medicaid enrollment.29 We find that while 15.7 percent of the sample reported
being enrolled in Medicaid at the time they completed the survey, 22.9 percent were actually enrolled at
some point during the year according to the CMS administrative records; this suggests an undercount
based on survey data of approximately 31.4 percent. Incorporating this underreport into our first stage
estimates indicates that the true first stage is likely closer to 14.7 percentage points (i.e., \(0.101(1-0.314)\)).

Because this analysis is based on the reporting behavior of Medicaid enrollees prior to the ACA, it
may not necessarily reflect the degree of underreporting among those gaining Medicaid coverage under
the ACA expansions. In addition, the degree of underreporting in the ACS may be larger than this
NHIS-based estimate since the NHIS is considered to have the most valid coverage estimates nationally
(Lynch et al., 2011).30 Therefore, we also estimate by how much we might be undercounting the
change in total Medicaid enrollment under the ACA by comparing the “first stage” we obtain from the
ACS with a “first stage” obtained from different CMS administrative data reports on total Medicaid
enrollment during the study period. The two different administrative sources available for this analysis

---

28See, for example, analyses in Sommers (2009) and Collins et al. (2018).
29Note we do not have access to similarly linked data for the ACS. These data are available from the National Center
for Health Statistics for NHIS respondents who consent to the linkage. Due to an unfortunately timed change in the way
CMS collects enrollee-level Medicaid administrative records, data are unavailable for most states after 2012.
30In contrast to the ACS, the NHIS uses state-specific names for Medicaid/CHIP in its coverage questions; it also
includes a verification question for the uninsured. In the Appendix, we estimate the impact of the expansions on Medicaid
coverage and uninsurance on our sample using the NHIS. The results are reported in Appendix Figure A1. We find
larger impacts of the Medicaid expansions on coverage using the NHIS than we do in the ACS. Medicaid enrollment
increases significantly in each post-expansion year by between 7.4 and 17.4 percentage points, and the average effect in
the post-expansion period is 13.6 percentage points. If we further adjust this for under-reporting, it suggests there was
an increase in Medicaid enrollment of 13.6/(1−0.314) = 19.8 percentage points.
offer different definitions of enrollment and have different information in terms of the years and states available, as well as the ages for which information on enrollment is collected. Depending on the data source used, we find estimates of undercount ranging from somewhat smaller (19%) to considerably larger (exceeding 100%) than the estimate arrived at with the NHIS-CMS linked data. Since the NHIS-CMS data analysis allowed us to create an analytic sample most similar to that used in this paper, we apply the 31.4 percent undercount estimate when discussing treatment effects in the section that follows. Additional details on the analysis of underreporting in the NHIS-CMS data, as well as the analyses involving the CMS administrative data reports may be found in Appendix Section C.

Taken together, our first stage analysis suggests that there were large and significant impacts of the ACA Medicaid expansions on eligibility, Medicaid enrollment, and coverage in our analysis sample.

### 4.2 Impact of ACA Expansions on Mortality

Our estimates of equation (1) are presented in Figure 2 and in the fourth column of Table 1. Prior to the ACA expansion, mortality rates trended similar across the two groups: pre-expansion event study coefficients are close to zero and not statistically significant. Starting in the first year of the expansion, we observe mortality rates decrease significantly among respondents in expansion states relative to non-expansion states. The coefficient estimated in the first year following the expansion indicates that the probability of dying in this year declined by about 0.089 percentage points. In years 2 and 3, we find reductions in the probability of a little over 0.1 percentage points and, in year 4, a reduction of 0.208 percentage points. All estimates are statistically significant.

In the difference-in-differences model, we estimate an average reduction in mortality of 0.132 percentage points (top panel of Table 1). We can combine this estimate with the estimates of the first stage to provide information on the treatment effect of Medicaid coverage on the group that actually enrolled.\(^{31}\) Our analysis of the ACS suggested that Medicaid enrollment increased by about 10.1 percentage points in our sample; when adjusted for survey under-reporting, the estimate is an increase of about 14.7 percentage points (see previous section). Our mortality estimates therefore suggest that the average treatment effect of Medicaid coverage on mortality is a reduction of about 0.898 percentage points (\(= 0.132 / 0.147\)).\(^{32}\)

It is important to note that the first stage only considers the immediate, or short-term, effects of Medicaid coverage on mortality. To the extent that there are longer-term effects on health, it is not clear that the average annual change in coverage is the correct first stage. For instance, individuals who gained coverage in 2014 but not later years may still experience health benefits that translate into reduced mortality in subsequent years. This is particularly relevant for the age group we study, as part of the sample ages in to Medicare over our analysis period. These individuals might still experience

---

\(^{31}\)One can further scale up this estimate to arrive at the local average treatment effect of gaining any insurance coverage by incorporating estimated crowd out of other coverage. However, this calculation ignores any potential benefits of Medicaid receipt for the already insured, such as a gain in coverage for certain services or the financial benefit of reductions in out-of-pocket medical costs. For example, individuals who switch to Medicaid from private insurance typically will not pay a premium and have minimal cost sharing, and could thus potentially benefit financially. The average annual premium for private coverage for a single person was $5,886 in 2013 (Claxton et al., 2013), representing approximately half of the federal poverty level for this year. It also builds in assumptions regarding the comparability of Medicaid and private insurance coverage. For this reason, we focus on the treatment effect of Medicaid coverage in this discussion, since this is the most direct measure of the condition being varied by the policy.

\(^{32}\)This effect would be somewhat smaller—about 0.667 percentage points—if we instead relied on the adjusted first stage estimated with the NHIS (i.e. a 19.8 percentage point increase in Medicaid coverage).
reduced mortality after enrollment in Medicare due to long-run health gains from receiving Medicaid at ages 62 to 64. Results in recent work examining the long-term effects of public insurance expansions for children document health improvements that manifest years later.\textsuperscript{33} A more appropriate first stage, if the data were available, might be the change in the proportion of the sample with any exposure to Medicaid at the time of each post-expansion year, which will necessarily be larger than the estimates presented here.

4.3 Placebo Tests and Additional Analyses

To assess the validity of our empirical approach, we conduct several “placebo” tests. In these tests, we investigate whether we observe effects of the Medicaid expansions in populations that we expect to be unaffected or less affected by the policy change.

Our first placebo tests uses individuals who were age 65 and older at the time of the ACA expansions. These individuals had near universal coverage through the Medicare program and should not have been directly affected by the coverage expansions.\textsuperscript{34} We re-estimate equation (1) for this sample and the results are presented in the first panel of Figure 3. As predicted, we observe no effect of the Medicaid expansions on Medicaid coverage for this group (panel a).\textsuperscript{35} We also see no effect of the ACA on mortality rates for this group.

A second placebo test shifts our analysis sample back in time to the pre-ACA period. This test can assess whether any elements of our sample construction, such as drawing the ACS sample only in the pre-expansion period, might lead to spurious results. We construct the data in the same fashion as our main analysis, but use mortality data from 2004 to 2013 for ACS respondents from 2004 to 2009 (rather than mortality data from 2008 to 2017 for 2008-2013 ACS respondents). We construct a variable indicating that a state expanded that corresponds to $Expansion_s$ in equation (1), but estimate our model as if the first expansions occurred in 2010 rather than 2014, with states expanding $t$ years after 2014 treated as if they expanded in 2010+$t$. The results of this placebo test using the pre-ACA period is presented in the second row of Figure 3.\textsuperscript{36} As expected, we find no effect on Medicaid coverage or mortality in expansion states during this pre-ACA period.

Finally, we examine individuals ages 55 to 64 in households earning 400% FPL or greater at the time of the ACS interview. This group should be less affected than our main sample of low income or low education respondents. However, they may still gain Medicaid coverage under the expansions due to changes in income over time, or if their income is reported with error. As seen in the third row of Figure 3, we do find small but statistically significant increases in Medicaid enrollment corresponding with the expansions among this group. We also see small but, for some years, statistically significant reductions in mortality for this group. However, these mortality reductions are quite small, between 15

\textsuperscript{33}Boudreaux et al. (2016) and Goodman-Bacon (2016) document better later life adult health among children who gained exposure to Medicaid under its rollout in the 1960s. Brown et al. (2018); Currie et al. (2008); Miller and Wherry (2018); Thompson (2017); Wherry and Meyer (2016) and Wherry et al. (2017) find evidence of better long-term health for children benefitting from later expansions in Medicaid and CHIP.

\textsuperscript{34}Prior work has documented some spillover effects on the health care utilization of this population under pre-ACA state Medicaid expansions, but analyses of the ACA Medicaid expansions have found no evidence of such spillovers and are able to rule out very small effects (Carey et al., 2018).

\textsuperscript{35}Results are similar if we also restrict the elderly to be in low income households.

\textsuperscript{36}Since the ACS only began collecting data on health insurance in 2008, the analysis for Medicaid coverage is limited to the 2008-2013 years.
and 20% of the size observed in our primary sample. The sample for the higher income group is also
nearly three times as large as our main sample, resulting in much tighter confidence intervals. Taken
together, all three placebo tests support our empirical design.

In addition to these placebo tests, we also conduct several additional analyses to further understand
the impact of the Medicaid expansions. First, we examine changes in death rates by the underlying
cause of death using the MDAC. These analyses rely on a much smaller sample and shorter follow-
up period, and so we consider this analysis to be exploratory in nature. We examine deaths due to
non-disease related (i.e. “external”) and disease-related (i.e. “internal”) causes separately. A subset
of deaths caused by internal factors are considered to be “health care amenable” (Nolte and McKee,
2003), which we also examine separately. These results are presented in Table A2. We observe similar
patterns for internal mortality and health care amenable mortality as we do in our main results, with
relative decreases beginning in the first year after the expansions occur. The event study coefficients
are not statistically significant for health care amenable mortality, and are significant at the $p < 0.10$
level for deaths from internal causes; however, we find a highly significant reduction in deaths related to
internal causes under the difference-in-differences model. In contrast, mortality from external causes,
which may be less affected by insurance coverage, does not appear to decrease after the expansions.
The point estimates on the event study indicators are not statistically significant and the difference-
in-differences estimate is only significant at the 10% level. The estimate is positive in sign, although
we note that there is a slight upward pre-trend in these deaths in the expansion states relative to
non-expansion states.

We further probe cause of death by conducting an analysis using the ICD code groupings by body
region. We emphasize that this exercise is meant to be exploratory with the hope that it will pro-
vide guidance for future work should better data become available. The results are reported in Table
A3. For most diseases, we observe negative coefficients; the largest negative point estimates are ob-
served for deaths related to neoplasms (cancer), endocrine and metabolic diseases (primarily diabetes),
cardiovascular and circulatory system diseases, and respiratory diseases. Two of these (cardiovascu-
lar/circulatory and endocrine/metabolic) are marginally significant at the 10% level. We also see a
small negative but statistically significant impact on diseases related to the skin and subcutaneous
tissue.

A second additional analysis uses our main data source but examines changes in mortality for
different populations. Our main analysis is limited to individuals ages 55 to 64 at the time of the
Medicaid expansions, a group with higher mortality rates that has been the focus of other work on this
topic (e.g. Black et al., 2019). In column (1) of Table A4, we also estimate the impact of Medicaid
expansion on mortality for individuals who meet our sample inclusion criteria but are ages 19 to 64 in
2014. As with the 55 to 64-year-old group, we find that mortality rates trended very similarly in the
two groups of states prior to the expansions, with the event study coefficients for the pre-expansion
years very close to zero (except for $y = -6$). Beginning in the first year of expansion, we see relative
decreases in mortality in the expansion states, although the estimates are much smaller in magnitude
than those observed for the 55-64 age group and only statistically significant in the second year following
implementation. In that year, we find a reduction in the probability of death of about 0.023 percentage
points. Interestingly, when combined with the first stage for this group (a 13.4 percentage point gain in
Medicaid coverage; these results available from the authors), the associated treatment effect is very close to that reported in the Oregon Health Insurance Experiment (although not statistically significant): about a 0.14 percentage point reduction in the probability of mortality, compared to their estimate of 0.13 percentage points (LATE estimate in Table IX in Finkelstein et al., 2012). Our estimate would be even smaller if we applied an adjustment for the underreporting of Medicaid coverage in the ACS survey.

Another additional analysis limits the main sample of 55 to 64 year olds to approximately a 30 percent subset who reported being uninsured at the time of the survey. These results are presented in the second column of Table A4. As this group is somewhat younger, the mean annual mortality rate is slightly lower than in the overall sample, at 1.1% mortality per year. This subsample also has fewer observations – 180,000 individuals (or 1.3 million individual by year observations) – resulting in wider confidence intervals. Nevertheless, we observe the same pattern of no pre-ACA changes and a relative decrease in mortality beginning at the time of expansion. The point estimates indicate somewhat larger decreases in mortality for this group of 0.150 percentage points (or 13.6% of the sample mean) compared to the reduction in the main sample of 0.132 percentage points (or 9.4% of the sample mean).

5 Interpreting the Estimates and Comparisons to Past Work

The above results present consistent evidence of a decrease in all-cause mortality among low socioeconomic status, older adults under the ACA Medicaid expansions. Our point estimate indicates an average decrease in annual mortality of 0.132 percentage points during the four-year post period, or a treatment effect of Medicaid coverage among those who enroll of 0.898 percentage points. To interpret the magnitude of this estimate, we must consider the mortality rate in the absence of Medicaid expansion. The average annual mortality rate in our sample is 1.4 percent. However, baseline mortality among those who actually enrolled in Medicaid (i.e., the “compliers,” see Imbens and Angrist, 1994) is potentially much higher. This will be the case if those in worse health are more likely to enroll in Medicaid. The literature indicates that such adverse selection does tend to occur (e.g. Kenney et al., 2012; Marton and Yelowitz, 2015); this may also be exacerbated by policies designed to provide immediate coverage to those in need, as discussed earlier (i.e. presumptive eligibility and retroactive coverage). Data from the 2014 National Health Interview survey linked mortality files indicate that Medicaid enrollees in the 55-64 age range have a 2.3 percent probability of death in the following year. We may therefore expect the mean mortality rate among the compliers to be somewhere in the 1.4 to 2.3 percent range. Combined with our estimated treatment effect of an 0.898 percentage point reduction in mortality, this indicates that Medicaid coverage reduces mortality by between 39% and 64%. Naturally, the uncertainty about both the size of the first stage and the baseline mean among the compliers results in a fairly large range of possible treatment effects. For this reason, we believe the focus should be primarily on the reduced-form estimates of the change in mortality for our overall sample, which was selected based on their likely eligibility for Medicaid, rather than these “back of the

\[^{37}\text{Our panel is aging over time and the mortality rate rises with age. As a result, comparing our estimates to the mortality rate in only the pre-ACA period as a counterfactual is incorrect. Instead, we opt to use the sample average as a point of comparison. Alternatively, one could use the baseline rate in the expansion states in the year just prior to expansion (1.3 percent) and apply an assumed increase in mortality with age during the post period, perhaps from the observed aging trajectory in the non-expansion states during the post period.}\]
envelope” treatment effect calculations.

Nevertheless, we further assess the plausibility of our estimates by comparing the treatment effect estimate to that in the OHIE. We use the public-use replication kit to examine the effect of Medicaid coverage on participants who were ages 55-64 at the time of the experiment to derive estimates comparable to those presented here. Among this group, receiving Medicaid reduced the probability of mortality over a 16 month period by 1.65 percentage points, or a decline of 71.7% relative to the control mean; this estimate is associated with a p-value of 0.128 (reported in Table A5). We scale this effect by 12/16th to arrive an annual effect of Medicaid on mortality of 1.24 percentage points. This is comparable, but larger, than the 0.898 percentage point treatment effect estimated here. Note that the very high baseline mortality rate among the OHIE control group is consistent with our assertion that the mortality rate among the compliers in our setting is also likely high.38 Since the OHIE participants are composed only of individuals applying for Medicaid, the high mortality rate is consistent with the idea that Medicaid applicants tend to be in poor health. In addition, we follow (Finkelstein et al., 2012) in our replication analysis and estimate the first stage as the difference in the probability a treatment group participant was ever enrolled in Medicaid; if we used a point-in-time enrollment measure, as we do in our analysis of the ACA expansions, the treatment effect in the OHIE would be even larger.39 Similar to the OHIE, when we examine the implied treatment effects from the existing quasi-experimental literature on Medicaid expansions for low-income adults, our estimates fall well within the range of observed effects (see Appendix Table A9 and Appendix Section D for detailed discussion).

6 Conclusion

There is robust evidence that Medicaid increases the use of health care, including types of care that are well-established as efficacious such as prescription drugs and screening and early detection of cancers that are responsive to treatment.40 However, due to data constraints, it has been difficult to demonstrate empirically that this increased utilization leads to improvements on objective measures of health, leading to widespread skepticism that Medicaid has any salutary effect on health whatsoever. Our paper overcomes documented data challenges by taking advantage of large-scale federal survey data that has been linked to administrative records on mortality. Using these data, we show that the Medicaid expansions substantially reduced mortality rates among those who stood to benefit the most.

Our estimated change in mortality for our sample translates into sizeable gains in terms of the number of lives saved under Medicaid expansion. Since there are about 3.7 million individuals who meet our sample criteria living in expansion states,41 our results indicate that approximately 4,800 fewer deaths occurred per year among this population due to Medicaid expansion, or roughly 19,200 fewer deaths over the first four years alone. Or, put differently, as there are approximately 3 million individuals meeting this sample criteria in non-expansion states, failure to expand in these states likely

---

38 The baseline mortality rate among the OHIE control group in the 55-64 age range is 2.3 percent over a 16 month period (A5). This corresponds to an annual mortality rate of 1.7 percent (i.e., $2.3 \times \frac{12}{16} \approx 1.7$), more than 20 percent higher than the average mortality rate in our sample.

39 By the end of the 16-month period, over a third of the individuals who ever enrolled in this age group were no longer enrolled in the program. Authors' calculations based on their analysis using the OHIE replication kit and data.

40 E.g. Finkelstein et al. (2012); Ghosh et al. (2019); Soni et al. (2018).

41 Authors’ calculation using the public-use ACS.
resulted in 15,600 additional deaths over this four year period that could have been avoided if the states had elected to expand coverage.\textsuperscript{42}

\textsuperscript{42}This relies on the assumption that effects of expansion in the non-expansion states would be similar to those observed in the expansion states.
References


Medicaid and CHIP Payment and Access Commission (2018). Medicaid Enrollment Changes Following the ACA.


State Health Access Data Assistance Center (2012, March). Defining ”Family” for Studies of Health Insurance Coverage. Technical Report Issue Brief #27, University of Minnesota, Minneapolis, MN.


Figure 1: Effect of the ACA Medicaid Expansions on Eligibility and Coverage

(a) Medicaid Eligibility
(b) Medicaid Coverage
(c) Uninsured

Note: These figures report coefficients from the estimation of equation (1) for the outcomes of Medicaid eligibility, Medicaid coverage, and uninsurance in the 2008-2017 American Community Survey. Note that scales differ across the three figures. The coefficients represent the change in outcomes for expansion states relative to non-expansion states in the six years before and four years after expansion, as compared to the year immediately prior to the expansion. The sample is defined as U.S. citizens ages 55-64 in 2014 who are not SSI recipients and who have either less than a high school degree or household income below 138% FPL. See Appendix Section B for detailed information on Medicaid eligibility determination.
Figure 2: Effect of the ACA Medicaid Expansions on Annual Mortality

Note: This figure reports coefficients from the estimation of Equation 1 for annual mortality. The coefficients represent the change in mortality for expansion states relative to non-expansion states in the six years before and four years after expansion, as compared to the year immediately prior to the expansion. The sample is defined as U.S. citizens ages 55-64 in 2014 observed in the 2008-2013 American Community Survey who are not SSI recipients and who have either less than a high school degree or household income below 138% FPL.
Table 1: Impact of the ACA Expansions on Coverage and Mortality: Difference-in-Differences Estimates

<table>
<thead>
<tr>
<th></th>
<th>Medicaid Eligibility Coverage</th>
<th>Medicaid Any Insurance Coverage</th>
<th>Died in Year Main Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Difference-in-Differences Model:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expansion × Post</td>
<td>0.428 (0.050)**</td>
<td>0.101 (0.012)**</td>
<td>-0.044 (0.010)**</td>
</tr>
<tr>
<td><strong>Event Study Model:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 3</td>
<td>0.406 (0.055)**</td>
<td>0.099 (0.120)**</td>
<td>-0.039 (0.012)**</td>
</tr>
<tr>
<td>Year 2</td>
<td>0.437 (0.046)**</td>
<td>0.108 (0.012)**</td>
<td>-0.050 (0.010)**</td>
</tr>
<tr>
<td>Year 1</td>
<td>0.430 (0.043)**</td>
<td>0.113 (0.010)**</td>
<td>-0.053 (0.011)**</td>
</tr>
<tr>
<td>Year 0</td>
<td>0.460 (0.039)**</td>
<td>0.073 (0.008)**</td>
<td>-0.038 (0.006)**</td>
</tr>
<tr>
<td>Year -1 (Omitted)</td>
<td>0.010 (0.005)*</td>
<td>-0.009 (0.007)</td>
<td>0.002 (0.006)</td>
</tr>
<tr>
<td>Year -2</td>
<td>0.016 (0.011)</td>
<td>-0.010 (0.007)</td>
<td>0.001 (0.006)</td>
</tr>
<tr>
<td>Year -3</td>
<td>0.014 (0.014)</td>
<td>-0.003 (0.008)</td>
<td>-0.007 (0.009)</td>
</tr>
<tr>
<td>Year -4</td>
<td>0.017 (0.015)</td>
<td>-0.001 (0.009)</td>
<td>0.000 (0.009)</td>
</tr>
<tr>
<td>Year -5</td>
<td>0.006 (0.020)</td>
<td>-0.006 (0.016)</td>
<td>-0.003 (0.015)</td>
</tr>
<tr>
<td>N (Individuals x Year)</td>
<td>714673</td>
<td>714673</td>
<td>714673</td>
</tr>
<tr>
<td>N (Individuals)</td>
<td>714673</td>
<td>714673</td>
<td>714673</td>
</tr>
</tbody>
</table>

Note: This table displays the event study coefficient estimates of equation (1). The sample is defined as U.S. citizens ages 55-64 in 2014 who do not receive SSI and who have either less than a high school degree or household income below 138% FPL. For models based on restricted-use data, sample sizes are rounded following Census disclosure rules. See text for more details. Significance levels: *=10%, **=5%, ***=1%. 
Figure 3: Placebo Tests

Age 65+ in 2014

(a) Medicaid Coverage

Pre-ACA Years

(b) Annual Mortality

Income 400%FPL +

(c) Medicaid Coverage

(d) Annual Mortality

(e) Medicaid Coverage

(f) Annual Mortality

Note: These figures plot coefficients from equation (1) for those age 65 and older in 2014 who would not have been affected by the Medicaid expansion due to their eligibility for the Medicare program (Row 1) and for those in higher income households who were likely less affected (Row 3). Row 2 plots the coefficients from (1) but uses pre-ACA years as a placebo test (see text for details).
A Additional Results
We present additional tables discussed in the main text in this section in Tables A1-A4. See the main text for further discussion of these results.

B First Stage Eligibility Estimates
To estimate the change in Medicaid eligibility associated with the ACA Medicaid expansions, we use the 2008-2017 ACS downloaded from IPUMS USA (Ruggles et al., 2019) and impute eligibility for our sample using state eligibility rules for each year. We consider eligibility for low-income parents under Medicaid Section 1931 criteria in each state, as well as expanded eligibility for parents and childless adults under waiver programs that offered comparable coverage to the ACA Medicaid expansions. We do not consider expanded programs that cover a more limited set of services and follow documentation from the Kaiser Family Foundation (KFF) to make this determination.

Information on state eligibility thresholds for coverage for adults were compiled from the sources listed in Table A6. The notes column in the table provides a record of any decisions made in applying the eligibility rules or to reconcile inconsistencies across different sources. KFF documentation on eligibility thresholds over time, which were used as our primary source, take into account state rules on earnings disregards when applicable. We defined the family unit for eligibility determination using the health insurance unit definition prepared by the State Health Access State Assistance Center, see details in State Health Access Data Assistance Center (2012). Following Medicaid rules for countable income (Centers for Medicare & Medicaid Services, 2016), we did not include family income from the Temporary Assistance for Needy Families or SSI programs in the calculation of total family income.

C Evaluating Survey Undercount of Medicaid Enrollment
To explore the extent to which survey measures undercount the number of individuals in our sample who were enrolled in Medicaid at any point during the survey year, we undertake several different analyses. Survey measures may undercount yearly enrollment because of respondents misreporting coverage or because a respondent correctly reports non-enrollment at the time of the survey but enrolls at a different point during the year. To examine this type of undercount, we take advantage of linked survey and administrative data on Medicaid coverage through the National Health Interview Survey via the public use NCHS-CMS Medicaid Feasibility Files. For each eligible respondent in the NHIS, these feasibility files state whether the respondent is present in the CMS MAX Person Summary (PS) file in each year.43 All Medicaid enrollees are included in the PS file if they were enrolled at any point

43Respondents were eligible for linkage if they were age 18 or older at the time of the survey and if they consented to have their administrative data linked.
during that year, even if they were enrolled for only a partial year. We can therefore compare presence in the PS file to self-reported Medicaid coverage in the NHIS for individuals meeting our sample criteria (i.e., citizens, not receiving SSI, age 55 to 64 in 2014 and either in households earning under 138% FPL or having less than a high school education).

Ideally we would perform this calculation during the 2014 to 2017 years. However, a change in the way CMS collected administrative data from state Medicaid offices occurred in 2013 and resulted in far fewer states providing the necessary administrative data for linkages. Since the public use NHIS file does not contain state identifiers, we limit our analysis to years in our sample period during which all states were available, i.e. the 2008 to 2012 waves of the NHIS.

Our results are presented in Table A7. We see that while that 15.7 percent of NHIS respondents meeting our sample criteria reported being enrolled in Medicaid when asked as part of the survey, 22.9 percent were found to be enrolled at some point during the year in the administrative records. Enrollment would therefore be undercounted by approximately 31.4 percent \((1 - \frac{15.7}{22.9} \approx 0.314)\) relying on survey data alone, motivating our re-scaling of the survey-based first stage estimates.

We also supplement this analysis by using administrative enrollment data published in two sets of CMS reports. We calculate the difference-in-differences estimate from each set of reports and compare it to an estimate derived from survey reports for a similar population in the ACS. The first set of reports come from administrative enrollment data published by CMS and compiled by the Kaiser Family Foundation (KFF). Beginning in July 2013, CMS has published monthly total enrollment numbers in their Medicaid and CHIP Application, Eligibility Determination, and Enrollment Data reports. The KFF has compiled these monthly reports and calculated pre-ACA average monthly Medicaid/CHIP enrollment during the period July-September 2013, as well as average Medicaid/CHIP monthly enrollment for each month during the post-expansion period (Kaiser Family Foundation, 2019c). These totals refer to the total number of unduplicated individuals enrolled in Medicaid and CHIP.

We combine these administrative totals with state population estimates from each year of the ACS to create enrollment rates. Using the average monthly enrollment rates for 2013 and the monthly enrollment rates for 2014-2017, we then estimate a difference-in-differences model that includes state, year, and month fixed effects. We follow the same definition and timing of Medicaid expansion, as well as exclude the 5 early expander states, as in our main mortality data analyses. We use population weights and cluster the standard errors at the state level. We then compare these estimates to those acquired using only ACS survey data over the same period.

The results are reported in Table A8. The estimates using CMS data show a larger rate of Medicaid participation at baseline and a larger increase in participation under the ACA Medicaid expansions when compared to the estimates using ACS data. The change associated with Medicaid expansion is 23% larger when estimated with the administrative data.

The second analysis uses the MAX validation reports, which report the total number of Medicaid enrollees by state as well as the percent of enrollees in the 45 to 64 age range. These data have two advantages over the KFF monthly reports: they report the total number of individuals ever enrolled during the year and they are available for a population closer in age to the group examined in the main study. However, there are two major disadvantages to these reports: they are only available
through 2014, and only for 16 states.\textsuperscript{44} Using these data, and the corresponding sample from the ACS, we conduct a similar comparison. These results are reported in columns 3 and 4 of Table A8. For this age group and set of states, we find a dramatically larger effect of the ACA expansions using the enrollment rates based on the administrative data – about an 8.6 percentage point increase in enrollment – compared to those derived from the ACS – an increase of only 2.6 percentage points.

D Comparisons to Prior Estimates

In the paper, we emphasize that our preference is to focus on the reduced-form intent-to-treat (ITT) estimates of the effects of the ACA Medicaid expansions on mortality rather than re-scaling the estimates into average treatment-on-the-treated (TOT) effects. The former tells us the effect of the policy on overall mortality, while the latter provides an estimate of the mortality change among those newly enrolled under the policy. However, to arrive at an estimate of the TOT effect, accurate information is required on the change in Medicaid enrollment under the policy, as well as the baseline mortality rate specific to the individuals induced to take up coverage. As we discuss in Section 5 of the paper, there is considerable uncertainty about the true size of both of these numbers.

However, when comparing our estimates to prior evidence on the mortality effects of Medicaid expansion, it is helpful to translate the ITT estimates into average TOT effects. There is variation in the magnitude of the policy changes studied in this literature, as well as differences in the baseline mortality of the populations studied. Therefore, converting these existing estimates into proportional TOT effects allows for the effect sizes to be compared more easily across these different policy environments.

In this section, we compare the effect sizes from our study to the existing literature. This exercise is inspired by a similar re-scaling of quasi-experimental estimates undertaken by Goodman-Bacon (2018b), which includes mortality effects of Medicaid observed for infants and children.\textsuperscript{45} Here, we focus on studies of changes in all-cause mortality under the ACA Medicaid expansions or similar insurance expansions for low-income adults.

We examine estimates for adults ages 55-64 when available, which is our primary age group of study, but we also examine estimates for all nonelderly adults.\textsuperscript{46} We calculate the implied effects for the newly Medicaid insured (i.e. TOT) by dividing the ITT effects reported in each paper by the corresponding change in Medicaid enrollment. In cases where the change in enrollment is derived from survey data, we apply the same adjustment for under-reporting of Medicaid coverage that we use for our own estimates, which assumes an undercount of 31.4% (see discussion in Section 4). In addition, we convert the estimates into proportional mortality effects using the reported baseline mortality rate. For studies other than our own that use aggregate mortality data (rather than data for poor adults), we apply an adjustment that multiplies the general population mortality estimate by 1.75 to account for the higher relative risk of death for poor adults.\textsuperscript{47} This adjustment factor is based on the discussion

\textsuperscript{44}These states are CA, GA, ID, IA, LA, MI, MN, MS, MO, NJ, PA, SD, TN, UT, WV, and WY.
\textsuperscript{45}Goodman-Bacon (2018b) also includes estimates of adult mortality under the pre-ACA Medicaid expansions in AZ, ME, and NY presented in Sommers et al. (2012). In our analysis here, however, we focus on newer estimates of the mortality effects under these expansions in follow-up work by Sommers (2017).
\textsuperscript{46}Note that Borgschulte and Vogler (2019) report reduced-form mortality effects for adults ages 55-64 but we have not included them here since the authors do not report a corresponding first stage.
\textsuperscript{47}We do not apply this adjustment in the case of Massachusetts health care reform, given that the expansion included higher income individuals. We also do not apply it for the analysis of patients initiating dialysis for end-stage renal disease.
presented in Sommers (2017). This assumes that the baseline mortality rate for poor adults is similar to
the baseline mortality rate for individuals newly gaining coverage under the Medicaid expansions (i.e.
the "compliers"). It is likely the to be the case, however, that the mortality rate for these individuals
is higher, given the evidence for the presence of adverse selection in insurance coverage decisions. If
so, the average TOT estimates presented here may be too large. We discuss this further in Section 5
in the text.

Note that we have chosen to present the average TOT estimates in terms of the effects among
individuals with newly gained Medicaid coverage, and not necessarily a change in insurance status.
This averages the mortality effects among individuals who gain any insurance coverage, as well as
those who would have otherwise had other sources of insurance coverage. In a few instances, when
authors reported first stage estimates for insurance coverage only and not Medicaid coverage, we used
estimates for the crowd-out of other sources of insurance coverage under the ACA Medicaid expansions
to estimate the corresponding changes in Medicaid coverage. We calculated these crowd-out estimates
using American Community Survey data and the methods described in Section 3.48

The resulting estimates are reported in Table A9. It is clear from this table that our estimates are
in the ballpark of those from existing work examining the mortality effects of Medicaid or insurance
expansions for adults. As discussed further in the text, our estimate of the proportional mortality
change among newly enrolled older adults is similar in magnitude to the IV estimate from the Oregon
Health Insurance Experiment (-64.0% vs. -71.7%). We should note, however, that the estimate for
this age group from the analysis in Black et al. (2019) is noticeably smaller. In addition, our estimate
for all nonelderly adults (-22.6%) is similar in magnitude to estimates from other studies of Medicaid
expansions and Massachusetts health care reform, which range from -16.3% to -29.2%. Finally, the
estimate for Swaminathan et al. (2018), which focuses on patients initiating dialysis for end-stage renal
disease, is -82.8%, indicating that the average treatment effect is high for individuals at increased
mortality risk.49

48Note that most of this “crowd-out” under the ACA expansions appears to be driven by an increase in private coverage
in states that did not expand Medicaid starting in 2014, presumably among those qualifying for subsidized coverage under
the exchanges (130-138% FPL) (Miller and Wherry, 2017). Therefore, we hypothesize that crowd-out might have been
smaller in magnitude during the pre-ACA Medicaid expansions, a period prior to the existence of subsidized exchange
coverage. In this case, the implied TOT effects might be larger than those reported here.

49Note, we did not apply an adjustment for higher baseline mortality for poor individuals with ESRD. If the same
adjustment is applied as in other analyses (x 1.75), then the proportional average TOT estimate is -47.3%.
Figure A1: Effect of the ACA Medicaid Expansions on Eligibility and Coverage, NHIS Analysis

Note: These figures report coefficients from the estimation of equation (1) for the outcomes of Medicaid coverage and uninsurance in the 2008-2017 National Health Interview Surveys. The coefficients represent the change in outcomes for expansion states relative to non-expansion states in the six years before and four years after expansion, as compared to the year immediately prior to the expansion. The sample is defined as U.S. citizens ages 55-64 in 2014 who are not SSI recipients and who have either less than a high school degree or household income below 138% FPL. In models where all post-expansion years are pooled (i.e., the “difference in differences” model), we find an increase in Medicaid coverage of 13.6 percentage points and a decrease in uninsurance of 5.8 percentage points; both estimates are significant at the 1% level.
<table>
<thead>
<tr>
<th></th>
<th>Expansion State</th>
<th>Non-expansion State</th>
</tr>
</thead>
<tbody>
<tr>
<td>% White</td>
<td>70.9</td>
<td>68.7</td>
</tr>
<tr>
<td>% Black</td>
<td>14.9</td>
<td>24.2</td>
</tr>
<tr>
<td>% Hispanic</td>
<td>15.3</td>
<td>12.2</td>
</tr>
<tr>
<td>% Uninsured</td>
<td>32.6</td>
<td>37.3</td>
</tr>
<tr>
<td>% Medicaid</td>
<td>20.5</td>
<td>16.2</td>
</tr>
<tr>
<td>% Less than High School Education</td>
<td>45.3</td>
<td>46.8</td>
</tr>
<tr>
<td>Average Age in 2014</td>
<td>55.8</td>
<td>55.9</td>
</tr>
<tr>
<td>Average Income relative to FPL</td>
<td>1.47</td>
<td>1.40</td>
</tr>
<tr>
<td>N</td>
<td>231,200</td>
<td>190,448</td>
</tr>
</tbody>
</table>

Note: This table displays weighted means for residents in expansion and non-expansion states meeting the sample criteria described in the text. These statistics were calculated using publicly-available 2008-2013 ACS data rather than the restricted version used in the main analysis.
Table A2: Impact of the ACA Expansions on Coverage and Mortality: Cause of Death

<table>
<thead>
<tr>
<th></th>
<th>Deaths from Internal Causes</th>
<th>Deaths from Health Care Amenable Causes</th>
<th>Deaths from External Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Difference-in-Differences Model:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expansion × Post</td>
<td>-0.002351 (0.006754)**</td>
<td>-0.0009097 (0.0005043)*</td>
<td>0.0003831 (0.0001998)*</td>
</tr>
<tr>
<td><strong>Event Study Model:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 1</td>
<td>-0.002207 (0.001262)*</td>
<td>-0.0004100 (0.0008170)</td>
<td>0.0000954 (0.0003947)</td>
</tr>
<tr>
<td>Year 0</td>
<td>-0.002090 (0.001081)*</td>
<td>-0.001029 (0.0007480)</td>
<td>0.0002501 (0.0003154)</td>
</tr>
<tr>
<td>Year -1 (Omitted)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Year -2</td>
<td>-0.0005340 (0.0008272)</td>
<td>0.0006530 (0.0005310)</td>
<td>-0.0000658 (0.0003380)</td>
</tr>
<tr>
<td>Year -3</td>
<td>0.0008772 (0.001038)</td>
<td>0.0001387 (0.0007171)</td>
<td>-0.0000658 (0.0004400)</td>
</tr>
<tr>
<td>Year -4</td>
<td>-0.0004416 (0.001118)</td>
<td>-0.0000797 (0.0008195)</td>
<td>-0.0003190 (0.0003844)</td>
</tr>
<tr>
<td>Year -5</td>
<td>0.0007490 (0.0009490)</td>
<td>0.0004741 (0.0007390)</td>
<td>-0.0002190 (0.0003696)</td>
</tr>
<tr>
<td>Year -6</td>
<td>0.0007098 (0.001062)</td>
<td>0.0002333 (0.0006164)</td>
<td>-0.0006014 (0.0003489)</td>
</tr>
<tr>
<td>N (Individuals x Year)</td>
<td>683000</td>
<td>683000</td>
<td>683000</td>
</tr>
<tr>
<td>N (Individuals)</td>
<td>88500</td>
<td>88500</td>
<td>88500</td>
</tr>
</tbody>
</table>

Note: This table displays the event study coefficient estimates of equation (1) using the MDAC. Sample sizes are rounded following Census disclosure rules. See text for more details. DRB Disclosure Approval #: CBDRB-FY19-310. Significance levels: *=10%, **=5%, ***=1%.
Table A3: Impact of the ACA Expansions on Mortality: Impact by ICD Grouping

<table>
<thead>
<tr>
<th>ICD Grouping</th>
<th>Expansion × Post</th>
<th>Mean</th>
<th>Expansion × Post</th>
<th>Mean</th>
<th>Expansion × Post</th>
<th>Mean</th>
<th>Expansion × Post</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious disease</td>
<td>-0.00000671 (0.0001273)</td>
<td>0.004121</td>
<td>-0.0005512 (0.0004556)</td>
<td>0.02718</td>
<td>0.0000337 (0.0000345)</td>
<td>0.0002675</td>
<td>-0.0004314 (0.0002277)*</td>
<td>0.005279</td>
</tr>
<tr>
<td>Neoplasms</td>
<td>-0.0000671 (0.0001273)</td>
<td>0.004121</td>
<td>-0.0005512 (0.0004556)</td>
<td>0.02718</td>
<td>0.0000337 (0.0000345)</td>
<td>0.0002675</td>
<td>-0.0004314 (0.0002277)*</td>
<td>0.005279</td>
</tr>
<tr>
<td>Diseases of the blood and blood-forming organs</td>
<td>-0.0000671 (0.0001273)</td>
<td>0.004121</td>
<td>-0.0005512 (0.0004556)</td>
<td>0.02718</td>
<td>0.0000337 (0.0000345)</td>
<td>0.0002675</td>
<td>-0.0004314 (0.0002277)*</td>
<td>0.005279</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases</td>
<td>-0.0000671 (0.0001273)</td>
<td>0.004121</td>
<td>-0.0005512 (0.0004556)</td>
<td>0.02718</td>
<td>0.0000337 (0.0000345)</td>
<td>0.0002675</td>
<td>-0.0004314 (0.0002277)*</td>
<td>0.005279</td>
</tr>
<tr>
<td>Mental/behavioral</td>
<td>-0.0000671 (0.0001273)</td>
<td>0.004121</td>
<td>-0.0005512 (0.0004556)</td>
<td>0.02718</td>
<td>0.0000337 (0.0000345)</td>
<td>0.0002675</td>
<td>-0.0004314 (0.0002277)*</td>
<td>0.005279</td>
</tr>
</tbody>
</table>

Note: This table displays the difference-in-differences coefficient estimates using the MDAC. Each entry is the result from a different regression. Rates are reported under coefficient estimates. Sample sizes are rounded following Census disclosure rules. DRB Approval Number: CBDRB-FY19-400. See text for more details. Significance levels: *=10%, **=5%, ***=1%.
Table A4: Impact of the ACA Expansions on Coverage and Mortality: Additional ACS Analyses

<table>
<thead>
<tr>
<th></th>
<th>Died in Year Ages 19-64</th>
<th>Died in Year, Uninsured at Time of ACS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Difference-in-Differences Model:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expansion (\times) Post</td>
<td>-0.0001900 (0.0001680)</td>
<td>-0.001500 (0.0006590)**</td>
</tr>
</tbody>
</table>

**Event Study Model:**

<table>
<thead>
<tr>
<th>Year</th>
<th>Died in Year Ages 19-64</th>
<th>Died in Year, Uninsured at Time of ACS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 3</td>
<td>-0.0003183 (0.0002191)</td>
<td>-0.002517 (0.0008802)**</td>
</tr>
<tr>
<td>Year 2</td>
<td>-0.0001270 (0.0001702)</td>
<td>-0.001425 (0.0009531)</td>
</tr>
<tr>
<td>Year 1</td>
<td>-0.0002309 (0.0001124)**</td>
<td>-0.001437 (0.0006387)**</td>
</tr>
<tr>
<td>Year 0</td>
<td>-0.0001541 (0.0001034)</td>
<td>-0.0008643 (0.0008343)</td>
</tr>
<tr>
<td>Year -1 (Omitted)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Year -2</td>
<td>-0.0000201 (0.0001146)</td>
<td>0.0001791 (0.0008579)</td>
</tr>
<tr>
<td>Year -3</td>
<td>0.0000318 (0.0001471)</td>
<td>-0.0005425 (0.0007373)</td>
</tr>
<tr>
<td>Year -4</td>
<td>-0.0000049 (0.0001663)</td>
<td>0.0001925 (0.0009295)</td>
</tr>
<tr>
<td>Year -5</td>
<td>0.0000138 (0.0001890)</td>
<td>0.001409 (0.001057)</td>
</tr>
<tr>
<td>Year -6</td>
<td>-0.0002170 (0.0002160)</td>
<td>0.0001959 (0.001126)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N (Individuals x Year)</th>
<th>23630000</th>
<th>1280000</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (Individuals)</td>
<td>3160000</td>
<td>1800000</td>
</tr>
</tbody>
</table>

Note: This table displays the event study coefficient estimates of equation (1) using the ACS. Sample sizes are rounded following Census disclosure rules. See text for more details. DRB Disclosure Approval #: CBDRB-FY19-310. Significance levels: *=10%, **=5%, ***=1%.
Table A5: Results from the Oregon Health Insurance Experiment for participants age 55-64 in 2008

<table>
<thead>
<tr>
<th>Alive</th>
<th>Control Group Mean</th>
<th>Reduced Form</th>
<th>2SLS</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.977</td>
<td>0.00422</td>
<td>0.0165</td>
<td>0.128</td>
</tr>
<tr>
<td>N</td>
<td>6550 (Control)</td>
<td>4240 (Treatment)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table uses the public-use replication kit of the Oregon Health Insurance Experiment to estimate the impact of Medicaid on individuals who were between the ages of 55 and 64 at the time of the experiment. The data and code were downloaded from https://www.nber.org/oregon/4.data.html.
<table>
<thead>
<tr>
<th>Year</th>
<th>Sources</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008-2010</td>
<td>Adults: NGA Center for Best Practices (2010), Table 9</td>
<td>We follow the criteria reported in Heberlein et al. (2011), Table 1 to determine whether programs described in NGA Center for Best Practices (2010) meet the full coverage criteria. We turned to additional sources to reconcile other differences with the program details reported in Kaiser Family Foundation (2019b). Specifically, we added a program for AZ following National Conference of State Legislatures (2009), a DC program based on Meyer et al. (2010), and altered HI and VT program details using Agency (2011).</td>
</tr>
<tr>
<td>2008-2017</td>
<td>Adults: Kaiser Family Foundation (2009)</td>
<td>We consider eligibility rules to be in place as of the date of the relevant KFF survey. To be consistent with estimates of implementation of the ACA Medicaid eligibility expansions, we consider the expansion in Indiana to take place in 2015.</td>
</tr>
<tr>
<td>2011-2017</td>
<td>Adults: Kaiser Family Foundation (2009)</td>
<td>We consider eligibility rules to be in place as of the date of the relevant KFF survey. To be consistent with estimates of implementation of the ACA Medicaid eligibility expansions, we consider the expansion in Indiana to take place in 2015.</td>
</tr>
<tr>
<td>2008-2017</td>
<td>Parents: Kaiser Family Foundation (2019a)</td>
<td>We consider eligibility rules to be in place as of the date of the relevant KFF survey. To be consistent with estimates of implementation of the ACA Medicaid eligibility expansions, we consider the expansion in Indiana to take place in 2015.</td>
</tr>
</tbody>
</table>
Table A7: Undercount Estimates from the NHIS-CMS Linked Feasibility Files

<table>
<thead>
<tr>
<th></th>
<th>% Reported Enrolled in Survey</th>
<th>% Reported Enrolled in Administrative Data</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.157 (0.007)</td>
<td>0.229 (0.008)</td>
<td>3,437</td>
</tr>
</tbody>
</table>

Note: This table displays the fraction of NHIS respondents meeting sample inclusion criteria who reported being enrolled in Medicaid in the NHIS (first row) versus those who were shown to be enrolled in Medicaid in the CMS administrative data (second row). Standard errors are in parentheses.

Table A8: Comparison of Medicaid Coverage Estimates: CMS vs. ACS

<table>
<thead>
<tr>
<th></th>
<th>All Ages and States, 2013-2017</th>
<th>Age 44-64, 17 States, 2012-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Enrollment Based on CMS Enrollment Reports</td>
<td>Enrollment Based on ACS Data</td>
</tr>
<tr>
<td>Expansion x Post</td>
<td>0.0382*** (0.0093)</td>
<td>0.0309*** (0.0049)</td>
</tr>
<tr>
<td>Baseline Mean in Expansion States</td>
<td>0.197</td>
<td>0.172</td>
</tr>
<tr>
<td>Number of Observations</td>
<td>2,103</td>
<td>14,323,891</td>
</tr>
</tbody>
</table>

Note: The first two columns in this table display the difference-in-differences estimates for analyses using monthly enrollment rates constructed from CMS enrollment reports and self-reported enrollment from the ACS for all ages, respectively, for the years 2013-2017. All regressions include state and year fixed effects and the regression with CMS data also includes month dummies. The second two columns display the DID estimates for analyses using total number of adults ages 45-64 ever enrolled in each year during 2012-2014 from the MAX validation reports from 16 states, as well as the estimates derived from a comparison ACS sample for those years. The regressions include state and year fixed effects. For all regressions, robust standard errors are clustered by state. The regressions with administrative data use state population estimates as weights, while the analyses with ACS data use survey weights. See text in Appendix Section C for more details on the data. Significance levels: *=10%, **=5%, ***=1%.
Table A9: Estimates for Annual Mortality Effects of Insurance Expansions for Adults (Deaths per 100,000)

<table>
<thead>
<tr>
<th>Population</th>
<th>ITT effect on mortality</th>
<th>First stage effect on Medicaid coverage</th>
<th>Implied mortality effect on new enrollees (i.e. average TOT)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline rate</td>
<td>Absolute change</td>
<td>Sources</td>
</tr>
<tr>
<td>Pre-ACA Medicaid expansion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finkelstein et al. 2012 (Oregon Health Insurance Experiment)</td>
<td>Adults ages 20-64 signing up for expanded Medicaid</td>
<td>800</td>
<td>-32 (-101.8 to 165.3)</td>
</tr>
<tr>
<td></td>
<td>Adults ages 55-64 signing up for expanded Medicaid</td>
<td>2300</td>
<td>-422 (-968.2 to 124.8)</td>
</tr>
<tr>
<td>Sommers 2017 (AZ, ME, NY expansions)</td>
<td>Adults ages 20-64</td>
<td>318</td>
<td>-19.1 (-31.4 to -6.8)</td>
</tr>
<tr>
<td>ACA Medicaid expansion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miller et al. 2019</td>
<td>Adults ages 19-64, below 138% FPL or low-ed, citizen, no SSI receipt</td>
<td>430</td>
<td>-19.0 (-13.9 to 51.9)</td>
</tr>
<tr>
<td></td>
<td>Adults ages 55-64, below 138% FPL or low-ed, citizen, no SSI receipt</td>
<td>1400</td>
<td>-132.0 (-229.4 to -34.6)</td>
</tr>
<tr>
<td>Black et al. 2019</td>
<td>Adults ages 55-64</td>
<td>854</td>
<td>-2.56 (-14.28 to 9.16)</td>
</tr>
<tr>
<td>Borgschulte and Vogler 2019</td>
<td>Adults ages 20-64</td>
<td>359</td>
<td>-11.36 (-18.4 to -4.3)</td>
</tr>
<tr>
<td>Swaminathan et al. 2018</td>
<td>Noneelderly patients initiating dialysis</td>
<td>6900</td>
<td>-600 (-1000 to -200)</td>
</tr>
<tr>
<td>Other insurance expansions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sommers, Sharon, and Baicker 2014 (MA health care reform)</td>
<td>Adults ages 20-64</td>
<td>283</td>
<td>-8.21 (-13.58 to -2.83)</td>
</tr>
</tbody>
</table>

Notes: OHIE estimates are measured over a 16-month, not 12 month period. Estimates from Black et al. (2019) are from the triple difference specification.

(1) Multiply baseline mortality rate by 1.75 to account for higher relative risk of death for poor adults, based on discussion in Sommers (2017).

(2) Applies estimates for crowdout (53.7% for ages 20-64 and 47.1% for ages 55-64) to estimate change in Medicaid coverage, based on authors' calculation from analysis of the ACA Medicaid expansions.

(3) Divide change in Medicaid coverage estimated from survey data by (1-0.314) to account for underreporting.